Bilaal.Raja
Company record

APYX  Apyx Medical Corp

Trailing twelve months to 2026-06-30, as filed 2026-08-06 and not restated since.
Healthcare

Scale

Market cap
$130m
Revenue TTM
$58m
Net income TTM
$-9m
Free cash flow
$-11m
Composite score
Sector rank
#2998

Valuation

P / E
EV / EBITDA
EV / sales
2.4
FCF yield
-8.49%
Yield vs 10-yr
-11.40pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.79% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-14.8%
EBITDA margin
-4.7%
ROE
-81.0%
ROIC
-19.3%
Revenue growth
25.6%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In the U.S., handpiece revenue accounts for more than 50% of our total Surgical Aesthetics revenue. We believe the increased use of GLP-1s had an initial negative impact on revenue for plastic and cosmetic surgeons and created uncertainty in the aesthetic space. We strongly encourage investors to visit our website: www.apyxmedical.com to view the most current news and to review our filings with the Securities and Exchange Commission. …Apyx Medical Corp, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →